Fundz

Lumexa Imaging

Raleigh, North Carolina, United States · Biotechnology, Health Care, Manufacturing

Lumexa Imaging is one of the nation’s largest providers of outpatient medical imaging, with a mission to expand access to advanced, high-quality, and affordable diagnostic care. We operate more than 180 centers across 13 states, including more than 85 centers in joint ventures with leading health systems. With over 5,000 team members and a clinical network of more than 1,000 subspecialized radiolo

Key facts

Headquarters
Raleigh, North Carolina, United States
Employees
5,000
Industries
Biotechnology, Health Care, Manufacturing
Status
Public (LMRI)
Website
www.lumexaimaging.com
LinkedIn
Company page

Recent activity at Lumexa Imaging

  • : SEC 8-K (7.01):
  • : SEC 8-K (1.01): On June 30, 2026, Lumexa Imaging, Inc. and Lumexa Imaging Outpatient, Inc. entered into an amendment to their existing Credit Agreement. This amended agreement provides a secured term loan facility of approximately $823 million and a revolving line of credit of $250 million. The term loan will bear interest either at SOFR plus 2.50% or the Prime Rate plus 1.50%, maturing in December 2032, while the revolving credit facility will have similar interest terms and is set to mature in December 2030. The amendment includes restrictive covenants that limit the Company’s subsidiaries in incurring additional debt and paying dividends, with specified financial covenants contingent on the revolving credit exposure. This strategic financial arrangement aims to strengthen the Company's capital structure while maintaining compliance with prescribed financial metrics.
  • : SEC 8-K (7.01):
  • : Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
  • : SEC 8-K (7.01): On April 8, 2026, Lumexa Imaging Holdings, Inc. provided a Regulation FD disclosure during a meeting and site visit where it reiterated its previously disclosed full year 2026 guidance. This event is significant as it indicates the Company’s confidence in meeting their financial projections amidst market conditions. The guidance outlined during this meeting is crucial for investors and stakeholders assessing the company's future performance and strategic direction.
  • : SEC 8-K (7.01):
  • : SEC 8-K (7.01):
  • : SEC 8-K (5.02): On January 12, 2026, Ms. Julie Szeker, who served as the Chief Legal Officer and Corporate Secretary of Lumexa Imaging Holdings, Inc., submitted her resignation effective March 13, 2026. The resignation was not due to any disagreements regarding the Company's operations or practices. As part of the transition, Ms. Szeker entered into a Transition Agreement which includes a transition payment of $450,000 and up to 12 months of subsidized healthcare coverage, contingent on her compliance with certain terms. Furthermore, Ms. Szykler is set to receive an annual bonus of $250,000 for her 2025 performance, to be paid alongside other employees. This transition process highlights the Company's efforts to manage leadership changes strategically.
  • : SEC 8-K (1.01): On December 17, 2025, Lumexa Imaging, Inc. and Lumexa Imaging Outpatient, Inc. entered into an amendment to their existing Credit Agreement, referred to as the Amended Credit Agreement. This agreement includes a secured term loan facility of $825 million and a secured revolving line of credit of $250 million. The term loan will bear interest at either SOFR plus 3.00% or the Prime Rate plus 2.00%, maturing in December 2032, while the revolving credit facility matures in December 2030 and is subject to covenants regarding debt and dividends. The financial implications involve substantial refinancing that restricts additional debt and includes a financial covenant concerning net leverage ratios. The agreement is guaranteed by virtually all wholly-owned subsidiaries of the Company, securing it against their assets.
  • : SEC 8-K (1.01): On December 12, 2025, Lumexa Imaging Holdings, Inc. closed its initial public offering (IPO) of common stock at a price of $18.50 per share, following its registration statement on Form S-1. The IPO is part of the company's strategic initiative to raise capital and expand its business operations. Significant agreements were executed in connection with the IPO, including an Underwriting Agreement. This transaction represents an important step for the company in its pursuit of growth and increased market presence, which could positively impact its financial standing and shareholder value.

Leadership

  • Kyle Lynch, Chief Growth Officer
  • Russell Stewart, Chief Medical Officer

Verified email and direct lines for Lumexa Imaging’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Lumexa Imaging files 1 employee benefit plan with the U.S. Department of Labor. The next plan year renews in Dec 2026.

Lumexa Imaging in the news

Companies similar to Lumexa Imaging

About Lumexa Imaging: questions and answers

What does Lumexa Imaging do?

Lumexa Imaging is one of the nation’s largest providers of outpatient medical imaging, with a mission to expand access to advanced, high-quality, and affordable diagnostic care. We operate more than 180 centers across 13 states, including more than 85 centers in joint ventures with leading health systems. With over 5,000 team members and a clinical network of more than 1,000 subspecialized radiolo

Where is Lumexa Imaging headquartered?

Lumexa Imaging is headquartered in Raleigh, North Carolina, United States.

How many employees does Lumexa Imaging have?

Lumexa Imaging has about 5,000 employees.

What is the latest news on Lumexa Imaging?

On Aug 12, 2026, SEC 8-K (7.01):

Is Lumexa Imaging a public company?

Yes. Lumexa Imaging is publicly traded under the ticker LMRI.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Lumexa Imaging across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.